Subject Index

A

agoraphobia 252
alcohol consumption 92
ANOVA 4, 64
  F Test 4, 9, 19
  approximate *F* test . . . . . 7, 18f.
antidepressive therapy 208
apples-and-oranges problem 149

B

Begg and Mazumdar test . . . . . 75f.
Behrens-Fisher problem 4
between-study variance . . . . 58, 64, 87, *see* heterogeneity
bias in meta-analysis 72, 75
  graphical methods . . . . . 72ff.
  statistical tests . . . . . 75ff.
body-mass-index (BMI) 91
breast cancer 91, 93
Brown-Forsythe test 6, 16
  modified 6, 17, 19

C

causal explanation 121
central venous catheter 187
chemotherapy 93, 199, 202
clinical trials 109, 120, 126, 208
  guidelines . . . . . 101ff.
  phase III 110, 118
  randomized . . 72, 80, 100, 104, 108
Cochran's test 5, 15
comparability of studies 90, 217
computer packages 159
  C.A.MAN 161
  META . . . . . 159, 163, 252ff.
confidence interval plot . . . . . 159, 252f.
correlation . . . . . *see* effect size
count data 156, 180, 187, 193
Cox regression 42, 44, 50
critical multiplism 135

D

depression 208
DerSimonian-Laird estimator 45ff., 58, 87, 184, 254
design variables . . . . . *see* explanatory variables
distribution
  binomial 160, 184, 255
  χ^2 . . . . . 27, 160
  poisson 185
dyspepsia 108

E

effect size 142, 183, 252
  (log) odds ratio . . . 181f., 185, 188f., 192
  (log) relative risk 42, 44, 50, 55, 72, 92, 181f.
  correlation 22
  number needed to treat 181
  response rate difference 210
  risk difference 181
  standard error of . . 26, 73, 183, 235, 238
  standardized difference . . . 22, 42f., 47, 49, 55, 75, 142
  standardized mortality ratio 42f., 47, 50
  transformation of . . . . . 25f.
  variance explained 237
efficiency 156, 181
Egger test . . . . . 76f.
EM-algorithm 161, 186, 255
enzyme-linked immunosorbent assays (ELISAs) . . . . . 167, 169, 171ff.
epidemiology 180, 208, 252
expectancy-value model . . . . 222, 226f., 234f., 240f.
explanatory variables . . . 134, 145, 169, 172, 175, 187, 192, 199f., 208, 210, 228

F

falsificationism 116

FDA ..... 117, 126f.
file-drawer hypothesis 230, 242
Fisher's z 26
fixed effects 118, 169
  confidence interval for MES 55
  deficiency of tests ..... 59ff.
  mean effect size (MES) 49, 55
  model .. 27, 54ff., 87, 109, 131, 238, *see* models
forest plot 72, 86
funnel plot 73, 86, 211f., 252

G

Galbraith plot 74, 86
garbage in – garbage out problem 149
generalizability theory 123
generalization 144
  Cook's principles ..... 125ff.
    applied to meta-analysis .. 129ff.
    causal explanation .... 127, 133f.
    discriminant validity 126f., 130ff.
    empir. inter- and extrapolation 127f., 132f.
    heterog. irrelevancies 125f., 130, 135
    proximal similarity ... 125, 129f.
  domains ..... 119f.
  empirical ..... 116, 119ff.
  logical 116
  meaning of ..... 115ff.
  theoretical 116
  transfer 117
  universals 116
generalized linear model 185, 199
  binomial model 185, 187
  ML-estimation 186
  poisson model 185, 187

H

heterogeneity .. 36, 83, 86, 91, 105, 160, 199, 252
  baseline ..... 182, 184, 189f.
  detection of ..... 86, 108, 160, *see* homogeneity
  distribution 43
  modeling of .. 161ff., 192, 205, 252, 254ff.
heterogeneity variance 42, 56, 188, 192, 254
  estimation of 42ff., 58, 61, 184, 200, 254
  nonparametric estimator 50
Hodgkin's disease 198
homogeneity 36, 43, 252
  modeling of 254
  test of 25f., 30, 35, 37, 54f., 57, 108, 160, 169, 171, 184, 192, 201, 210, 240, 254
hygiene in hospitals 180

I

inclusion/exclusion criteria 88, 90
independence assumption 174
inference
  deductive 115
  inductive 115
integrative reviews 135
intention to treat analysis 108
ischaemic heart disease 191
iterative reweighting 200

K

Kaplan-Meier estimator 50

L

language bias 72

M

maximum likelihood
  nonparametric approach 161, 186, 189, 192
maximum partial likelihood estimator (MPLE) ..... 44, 47f.
mean effect size (MES) 25, 31, 72, 86f., 180, 183ff., 188f., 239, 254
  bias of 28
  confidence interval 26, 28, 32f., 184
  significance of ..... 26, 34, 183f.
  variance of 25, 183
Mehrotra test ..... *see* modified Brown-Forsythe test
meta-analysis
  and theory development .... 146f.
  approaches 23, 142
    classification of 27
    Hedges-Olkin ..... 24f.
    Hunter-Schmidt 24f., 142
    Rosenthal-Rubin ..... 24f.
  bias ..... *see* bias in meta-analysis
  conducting 107
  critique of ..... 80, 100, 149f.
  generalizability of inferences .. 129

increasing credibility of .....104ff.
objectives .....104ff.
of diagnostic tests 166
of literature (MAL) 80f., 83
of patient data (MAP) ... 80f., 83f., 107
planning of .....106f.
presentation of results ..... 107ff.
prospective ..... 81, 84, 91, 102f.
reasons for 82
recommendations for use of .. 103
steps 85
meta-regression 88, 238
mixed logistic regression 169, 172, 175, 189, 191
mixing distribution 161, 256
mixture distribution 161
analysis ..... 156, 187, 189f., 254f.
models
choice between fixed and random effects 63, 238
combined decision rules .....63f.
comparison between fixed and random effects .....87f.
mixture 256
moderator
analysis 142f., 172ff., 225
effects 126f., 131, 134, 144
example 143
mono-operation bias 130
multicenter studies .. 81, 84, 105, 201f., 211
multivariate models 175

N

narrative review 81, 83, 220
Nelson estimator 51
nonparametric MLE .... *see* maximum likelihood

O

odds ratio ..... *see* effect size
orthogonal contrast 210
overall treatment effect .... 54, 103, *see* mean effect size (MES)
overdispersion 175

P

pharmaceutical
production 43, 156
products 117
pivotal trials 100, 105, 107, 109, 111
placebo 108, 214
response 131f., 215
run-in 211, 216
pooled estimate ... *see* mean effect size (MES)
posterior distribution 162
principle of compatibility ..... 228ff.
program evaluation 123
psychotherapy ..... 126, 129ff.
publication bias 72, 83, 86, 88, 104, 211

Q

quality assurance 156
heterogeneity in 156
meta-analytical modeling in .. 158
mixture distribution analysis in 156
quality control 156, 159
quality scores 42, 44, 48, 52
quasi-experiments 80, 116, 208

R

radial plot 74, 86
random effects 36, 118, 169, 192
conditional 36, 131
confidence interval for MES 57
deficiency of tests .....59ff.
mean effect size (MES) 56
model .....27, 43, 54, 56f., 87, 131, 142, 183f., 188f., 238, 252, *see* models
model assumptions 44
receiver operating characteristic ...166
regulatory setting ... 101, 104, 107, 111
relative risk ..... *see* effect size
repeated measurements 168
replication 110, 118
representative designs 119
risk estimation .....90f.
robustness of effects 118, 135

S

sampling theory .....121f.
second order sampling error 28
secondary analysis .....233ff.
self-reference effect 143
sensitivity .....169ff.
sensitivity analysis 88, 103, 105
software ..... *see* computer packages
specificity .....169ff.
standardized difference *see* effect size

standardized mortality ratio *see* effect size
study characteristics . . *see* explanatory variables
subgroup analysis 107, 110
survival rates 199, 203

T
technology transfer . . . . . 117f.
tests
of association 54
theory of planned behavior 223
theory of reasoned action . . . . . 220ff.
treatment cells 209
Trichinellosis 167
Type I error rate 30, 35, 54, 66, 134

V
validation studies 166
validity
construct 125
external . . . . . 122ff.
internal 122, 124
variance decomposition . . . . . 44f.

W
Welch test 5, 14, 19
adjusted 7, 18
within-study variance 58, 65